Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -560.2%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $40M | $9M | $5513 | $8400 | $12600 | $9090 | $3600 | — | $956250 | $196M |
| Enterprise Value | $2M | $32M | $12M | $-4367488 | $-12356600 | $-11394400 | $-1340910 | $-5575400 | — | $5M | $201M |
| P/E Ratio → | -0.56 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.88 | 7.65 | 1.52 | 0.00 | 0.04 | — | 0.03 | 0.00 | — | 0.15 | 17.22 |
| P/B Ratio | 3.15 | 9.98 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | 17.82 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.13 | 2.09 | -0.89 | -55.16 | — | -4.43 | -0.80 | — | 0.78 | 17.66 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.5% | 91.5% | 85.4% | -97.2% | -217.9% | — | -791.1% | 100.0% | 61.5% | 79.4% | 76.1% |
| Operating Margin | -293.5% | -293.5% | -252.3% | -271.1% | -8800.0% | — | -3163.0% | -52.3% | -293.7% | -322.6% | -173.2% |
| Net Profit Margin | -429.4% | -429.4% | -222.8% | -271.0% | -9051.3% | — | -2719.8% | -155.6% | -423.5% | -353.9% | -193.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -560.2% | -560.2% | — | -522.5% | -234.7% | -193.3% | -393.3% | -341.0% | -138.6% | -189.2% | -190.1% |
| ROA | -195.0% | -195.0% | -144.0% | -75.5% | -88.4% | -78.6% | -46.6% | -46.1% | -45.4% | -68.5% | -61.0% |
| ROIC | — | — | — | — | — | -1688.1% | — | -56.3% | -42.1% | -93.6% | -96.6% |
| ROCE | -381.4% | -381.4% | — | -210.2% | -140.2% | -127.0% | -155.7% | -48.2% | -89.3% | -117.2% | -76.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | — | — | 0.89 | 0.65 | 2.31 | 10.32 | 2.72 | 1.05 | 1.61 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.99 | — | — | -1.92 | -1.05 | -0.45 | -4.81 | 1.71 | 0.31 | 0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.24 | -4.24 | -2.48 | -33.72 | -27.52 | -13.38 | -7.95 | -0.77 | -3.62 | -10.07 | -7.51 |
Net cash position: cash ($9M) exceeds total debt ($821000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.37 | 0.55 | 0.81 | 1.50 |
| Quick Ratio | 1.23 | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.36 | 0.54 | 0.63 | 1.20 |
| Cash Ratio | 0.71 | 0.71 | 0.23 | 0.80 | 1.53 | 3.13 | 0.98 | 1.21 | 0.30 | 0.52 | 1.00 |
| Asset Turnover | — | 0.32 | 0.88 | 0.43 | 0.01 | — | 0.03 | 0.30 | 0.12 | 0.20 | 0.33 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 10.73 | 0.41 | 0.73 |
| Days Sales Outstanding | — | — | 35.79 | — | — | — | 71.07 | 68.48 | 28.51 | 14.63 | 41.47 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 4.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 100.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 4.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 100.0% | 0.0% |
| Shares Outstanding | — | $3M | $308030 | $126 | $70 | $32 | $12 | $4 | $0 | $17 | $692 |
Clinical trial funding dependency
According to recent market data, PSTV trades at a price-to-sales ratio of 1.95, a multiple that appears disconnected from the firm's lack of commercial revenue and suggests investors are pricing in binary outcomes rather than fundamental earnings power or sustainable growth trajectories for the radiopharmaceutical pipeline.
The current valuation reflects a high-risk premium typical of pre-revenue biotechnology firms where traditional metrics like P/E are non-meaningful. Investors should monitor whether this multiple compresses further as the company approaches potential liquidity events, as the market may be overestimating the probability of near-term clinical success.
As reported in financial statements, the company maintains a gross margin of 89.4% in 2026Q1, yet this figure is misleading as it stems from non-recurring grant income rather than commercial operations, resulting in a persistent operating margin of -6.9% that highlights the firm's inability to cover research costs.
The high gross margin is an accounting artifact of grant-funded research and should not be interpreted as a proxy for future commercial profitability. True earning power remains negative, and the company's reliance on external capital to fund its R&D-heavy cost structure warrants significant caution regarding long-term margin sustainability.
Based on reported figures, the company's ROIC of -186.6% in 2026Q1 underscores a severe inability to generate returns on invested capital, reflecting the high costs of convection-enhanced delivery trials that have yet to produce a marketable asset or a path toward self-sustaining economic value creation.
The negative return on capital is characteristic of a firm in the early stages of clinical development, but the magnitude of the decay suggests that capital is being consumed at a rate that outpaces the clinical progress achieved. This trend implies that shareholders are effectively subsidizing the research infrastructure without a clear line of sight to future compounding returns.
According to recent quarterly filings, the current ratio of 2.27 in 2026Q1 provides a superficial appearance of stability, yet this liquidity is rapidly depleting as the company burns through cash to support its specialized radiopharmaceutical manufacturing and clinical trial site operations in a high-cost environment.
While the current ratio suggests an ability to meet short-term obligations, the rapid depletion of cash reserves indicates that the company's liquidity position is highly vulnerable to clinical trial delays. Investors should monitor the cash runway closely, as the firm's reliance on external financing remains the primary determinant of its ongoing operational viability.
Based on the company's unique business model, the price-to-sales ratio is the most commonly misapplied metric, as it obscures the fact that PSTV's revenue is derived from non-recurring research grants rather than commercial product sales, rendering traditional top-line valuation comparisons largely irrelevant for assessing the firm's true worth.
Analysts should instead focus on cash burn rates and clinical milestone progress, as these are the true drivers of value for a pre-commercial radiopharmaceutical company. Using P/S ratios to value PSTV risks creating a false sense of commercial traction where none currently exists, potentially leading to significant mispricing of the equity.
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PSTV stock.
Plus Therapeutics, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Plus Therapeutics, Inc.'s return on equity (ROE) is -560.2%. The historical average is -181.6%.
Based on historical data, Plus Therapeutics, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Plus Therapeutics, Inc. has 91.5% gross margin and -293.5% operating margin.